Product Datasheet

IAM1363

Catalog No. **BP-07691** · CAS **3031413-24-5** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-11-13**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
EGFR	**Cancer**

Molecular formula	$C_{30}H_{33}N_9O_2$
Molecular weight	**551.6421**

STRUCTURE



DESCRIPTION

IAM1363 is a selective, irreversible, and blood-brain barrier-permeable HER2 inhibitor . IAM1363 targets wild-type HER2 and oncogenic HER2 mutants (including exon 20 mutations), with no off-target EGFR inhibitory activity. IAM1363 can be used to study HER2-driven solid tumors, including colorectal cancer, non-small cell lung cancer, bladder cancer, and breast cancer .

BIOLOGICAL ACTIVITY

IAM1363 exhibits preferential tumor enrichment in preclinical studies, a unique feature observed across different tumor types and anatomical sites

SOLUBILITY

Soluble in DMSO : 100 mg/mL

In vitro	DMSO : 100 mg/mL

REFERENCES

[1].Adjei A A, et al. IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors[J]. 2024.

[2].Huang Z J, et al. P3. 03.29 IAM1363 Is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC[J]. Journal of Thoracic Oncology, 2025, 20(10): S441.